p53 Gene Mutations Occurring in Spontaneous Benign and Malignant Mammary Tumors of the Dog

Abstract

Sixty-three cases of benign and malignant canine mammary tumors were analyzed to define the alteration of exons 5-8 for the p53 tumor suppressor gene using polymerase chain reaction direct sequence analysis with paraffin-embedded tissues. Four missense mutations were found in 38 benign mammary tumors (11%), and five missense (one tumor had two missense mutations) and one nonsense mutations were found in 25 mammary carcinomas (20%). These data suggest that the p53 gene alterations might be initiated at an early stage of canine mammary carcinogenesis and p53 mutations might be associated with malignancy. However, there was no evidence of any relationship between the p53 alterations and the histologic types of tumors or breeds of dogs.

Canine tumour suppressor gene p53 mutation in a case of anaplastic carcinoma of the intestine

“…Remarkably, several canine position 249 point mutations reported so far are CGG → TGG transitions (arginine → tryptophan). They concerned two mammary (Mayr et al, 1998;Muto et al, 2000) and one circumanal gland tumour (Mayr et al, 1997).…”

“…In dogs, p53 alterations have been detected in cases of mammary tumours (Van Leeuwen et al, 1996;Chu et al, 1998;Mayr et al, 1998;Mayr et al, 1999;Veldhoen et al, 1999;Muto et al, 2000), lymphoma (Veldhoen et al, 1998;Nasir and Argyle, 1999;Setoguchi et al, 2001), osteosarcoma (Van Leeuwen et al, 1997;Johnson et al, 1998;Setoguchi et al, 2001), thyroid tumour (Devilee et al, 1994;Setoguchi et al, 2001), papilloma (Mayr et al, 1994), skin tumours (Mayr et al, 1999), colon cancer (Setoguchi et al, 2001) and circumanal gland tumour (Mayr et al, 1997). However, apart from the above-mentioned colon cancer (Setoguchi et al, 2001) virtually no data are available regarding neoplasms of the small and large intestine.…”

Canine Mammary Tumors: Risk Factors, Prognosis and Treatments

“…The p53 tumor suppressor gene encodes a protein which normally regulates cell cycle and programmed cell death, and its mutations are known to contribute to the carcinogenic process of various organs, including the mammary gland (Greenblatt et al, 1994). In CMT, p53 mutations have been detected in both benign and malignant types (Muto et al, 2000;Lee and Kweon, 2002;Kumaraguruparan et al, 2006).…”

12_Prospective Study of Tumor Markers as Prognostic Factors in the Histopathological Differential Diagnosis of Mammary Gland Neoplasms in Female Canines

“…Mutation of the p53 gene plays an important role in the uncontrolled proliferation and resistance to apoptosis in cancer cells , leading to functional changes in proteins. In dogs, expression of the p53 gene was found in both benign (Muto et al, 2000) and malignant (Mayr et al, 1994;Veldhoen et al, 1999) tumors of mammary gland. Muto (2000) in his study showed no association between p53 expression and histological type of cancer, but claimed that this protein may play an important role in carcinogenesis and may be a negative prognostic factor (Muto et al, 2000).…”

“…In dogs, expression of the p53 gene was found in both benign (Muto et al, 2000) and malignant (Mayr et al, 1994;Veldhoen et al, 1999) tumors of mammary gland. Muto (2000) in his study showed no association between p53 expression and histological type of cancer, but claimed that this protein may play an important role in carcinogenesis and may be a negative prognostic factor (Muto et al, 2000). Chung-Ho (2004) came to a similar conclusion, arguing that the presence ofp53 in tumor cells is associated with their malignancy and bad prognosis in mammary gland tumors (Chun-Ho et al, 2004).…”